Skip to content
BHP

Research peptides in hypoactive sexual desire disorder (HSDD)

Reviewed by the BestHealingPeptides Editorial Team ·

Hypoactive sexual desire disorder (HSDD) is characterised by persistently low sexual desire causing personal distress, occurring in the absence of medical or psychiatric explanation. Historically pharmacologically intractable, HSDD has become a live pharmaceutical research space through the melanocortin receptor system — specifically through central MC4R activation, which drives sexual arousal via central nervous system mechanisms distinct from the peripheral vascular pharmacology of PDE5 inhibitors. PT-141 (bremelanotide) is the FDA-licensed melanocortin agonist for HSDD in premenopausal women; Melanotan II is the pharmacological precursor from which PT-141 was derived, though Melanotan II carries MHRA warnings for melanoma and naevus concerns. The pre-clinical and clinical melanocortin pharmacology across these compounds establishes the current best-characterised pharmacological approach to central arousal deficit.

PT-141 (bremelanotide) is the first pharmacological compound specifically licensed for female HSDD acting through central nervous system mechanisms rather than peripheral vascular pharmacology. FDA approval in 2019 (as Vyleesi) established the melanocortin arousal-pharmacology approach as clinically viable and opened a therapeutic space that had been pharmacologically intractable through PDE5 inhibitors, hormonal interventions, and non-melanocortin approaches.

— Notable finding

Condition background

HSDD is defined in DSM-5 and ICD-11 as persistently or recurrently deficient sexual thoughts, fantasies, and desire for sexual activity causing marked personal distress or interpersonal difficulty, and not better explained by another mental disorder, effects of substances, or general medical condition. Prevalence estimates range from approximately 8-14% of adult women with distress-associated criteria applied, though epidemiological estimates vary substantially with definition and measurement instrument. HSDD is distinct from other female sexual dysfunctions (arousal, orgasm, pain disorders) though comorbidity is common. In premenopausal women specifically, HSDD often occurs without identifiable medical, hormonal, or relational cause and has historically been pharmacologically intractable — hormonal (testosterone, oestrogen) interventions have limited efficacy and safety profiles, and PDE5 inhibitors (sildenafil, tadalafil) that address vascular erectile function in men are ineffective for HSDD because the deficit is central rather than peripheral. HSDD in postmenopausal women additionally involves hormonal contributions that are addressed through separate menopause-management pathways.

Current treatment landscape

Current pharmacological options for HSDD in the UK are limited. Flibanserin (Addyi) is a serotonin 5-HT1A agonist / 5-HT2A antagonist licensed by FDA for HSDD in premenopausal women but not currently available on the UK market. Bremelanotide (Vyleesi, the PT-141 licensed product) is FDA-approved as-needed injection for HSDD in premenopausal women but similarly not licensed by MHRA. Off-label testosterone therapy is used in some UK gender-clinic and specialist-menopause contexts for postmenopausal HSDD; efficacy is modest and safety concerns exist. Psychosexual therapy and cognitive-behavioural approaches remain the mainstay for premenopausal HSDD in the UK given the absence of licensed pharmacological options. Research and pre-clinical characterisation of the melanocortin approach continues to expand the pharmacological toolkit.

Why peptides are studied here

The melanocortin receptor system — specifically the MC4R receptor expressed in hypothalamic and brainstem sexual-function circuits — drives sexual arousal through central nervous system mechanisms fundamentally distinct from the peripheral vascular mechanisms of PDE5 inhibitors. This central pharmacology addresses the pharmacological gap that PDE5 inhibitors cannot fill for either male or female arousal deficits. [PT-141 (bremelanotide)](/peptides/pt-141) is a selective melanocortin agonist derived from Melanotan II, modified to reduce MC1R-mediated pigmentation activity while preserving MC4R-mediated central arousal effects. FDA-licensed as Vyleesi for HSDD in premenopausal women, PT-141 represents the current best-characterised melanocortin arousal pharmacology and the first pharmacological approach specifically targeting central female arousal deficit. [Melanotan II](/peptides/melanotan-ii) is the pharmacological precursor to PT-141 with additional MC1R agonist activity producing pigmentation effects; research on Melanotan II's sexual-function effects established the melanocortin arousal framework that was subsequently refined in PT-141 development. Melanotan II carries MHRA warnings for melanoma and dysplastic naevus concerns and is not clinically appropriate for HSDD despite the mechanistic overlap. Ongoing research on selective MC4R agonists and next-generation melanocortin pharmacology continues to expand the therapeutic space.

Relevant research peptides

Notable study findings

  • PT-141 (bremelanotide)

    In the Phase III RECONNECT trials of premenopausal women with HSDD, PT-141 as-needed subcutaneous administration produced statistically significant improvements in Female Sexual Function Index (FSFI) desire domain and Female Sexual Distress Scale-Desire/Arousal/Orgasm scores versus placebo, supporting FDA approval as Vyleesi in 2019.

  • PT-141 (mechanism)

    Central MC4R activation by PT-141 drives sexual arousal effects through hypothalamic and brainstem sexual-function circuits independently of vascular smooth-muscle effects — a fundamentally different mechanism from PDE5 inhibitors and the pharmacological basis of the licensed HSDD indication.

  • Melanotan II (historical)

    Early pharmacological characterisation of Melanotan II established the melanocortin arousal framework subsequently refined in PT-141 development — although MHRA warnings for melanoma and dysplastic naevus concerns preclude clinical use of Melanotan II itself for HSDD.

UK regulatory notes

PT-141 (bremelanotide, Vyleesi) is licensed by FDA for HSDD in premenopausal women but is not currently MHRA-licensed in the UK. Prescription access requires either private-clinic prescribing through international pharmacy channels or NHS specialist-centre involvement in the small number of contexts where private importation is arranged. Melanotan II is not licensed anywhere and MHRA has issued explicit public warnings against its use given melanoma and naevus safety concerns. Neither PT-141 nor Melanotan II is on the current WADA Prohibited List. Research use of these compounds in appropriate laboratory contexts is not restricted by UK medicines law; supply for human use engages the Human Medicines Regulations 2012.

Frequently asked questions

What is HSDD?
Hypoactive sexual desire disorder (HSDD) is characterised by persistently deficient sexual thoughts, fantasies, and desire for sexual activity causing personal distress, not better explained by another mental disorder or medical condition. Prevalence estimates in the adult female population range from approximately 8-14% with distress criteria applied.
How does PT-141 differ from sildenafil (Viagra) for arousal deficits?
PT-141 (bremelanotide) acts through central nervous system MC4R activation to drive sexual arousal independently of vascular mechanisms. Sildenafil and other PDE5 inhibitors act on peripheral nitric oxide-mediated smooth muscle relaxation in erectile tissue. The two mechanisms are complementary rather than substitutive — PDE5 inhibitors address peripheral vascular erectile function; PT-141 addresses central arousal deficit. This is the mechanistic basis of PT-141's licensed HSDD indication where PDE5 inhibitors are ineffective.
Is PT-141 available in the UK?
PT-141 (bremelanotide, Vyleesi) is FDA-licensed for HSDD in premenopausal women in the US but is not currently MHRA-licensed in the UK. Access requires private-clinic international importation or specialist-centre arrangements. Research use in appropriate laboratory contexts is not restricted by UK medicines law.
Why is Melanotan II inappropriate for HSDD despite the mechanistic overlap?
Melanotan II is the pharmacological precursor to PT-141 with additional MC1R agonist activity producing pigmentation effects. MHRA has issued explicit public warnings against Melanotan II use given melanoma and dysplastic naevus safety concerns — the pigmentation-driving MC1R activity accelerates melanocyte proliferation with associated cancer-risk implications. PT-141 was specifically engineered to reduce MC1R activity while preserving the MC4R-mediated arousal pharmacology.
Does PT-141 work for male sexual dysfunction as well?
PT-141 was investigated in Phase II trials for erectile dysfunction (particularly for men non-responsive to PDE5 inhibitors) with encouraging efficacy but ultimately did not progress to registration for the male indication. The compound's central-arousal mechanism is applicable to both sexes; the licensed indication in premenopausal women reflects the trial-design and regulatory-strategy trajectory rather than sex-specific mechanism limitations.
What are the common adverse effects of PT-141?
Nausea is the most common adverse event, affecting up to 40% of subjects in clinical trials and typically dose-related. Facial flushing, injection-site reactions, and headache also occur. Transient blood pressure elevation is documented at higher doses. Serious adverse events are uncommon. The as-needed rather than daily dosing pattern helps manage adverse-event tolerability.
Are there next-generation MC4R agonists in development for HSDD?
Setmelanotide (Imcivree) is an MC4R-selective agonist licensed for rare genetic obesity syndromes rather than HSDD; ongoing pharmacological development of additional MC4R agonists continues to explore both metabolic and arousal-pharmacology applications. Selective MC4R pharmacology remains an active research area with implications across obesity, sexual function, and other MC4R-mediated indications.

Where to source research peptides for laboratory research

The following UK-based suppliers stock research-grade, lyophilised peptides for in-vitro and pre-clinical work. Purity and provenance vary; always request a Certificate of Analysis (CoA) and confirm cold-chain storage on arrival. None of the products linked below are approved for human use.

  • PeptideAuthority.co.uk

    UK-based research peptide supplier with batch certificates of analysis and >99% purity testing.

  • PeptideBarn.co.uk

    Wide catalogue of research-grade lyophilised peptides shipped from the UK, including bulk vials.